• InnoCare Pharma presented results from three orelabrutinib studies at the European Society for Medical Oncology Congress 2026.
• A Phase 2 trial combining orelabrutinib with zuberitamab showed durable responses in previously untreated marginal zone lymphoma, with manageable safety.
• Another Phase 2 study showed sustained benefit in relapsed or refractory chronic lymphocytic leukemia, with favorable long-term safety.
• A retrospective study found orelabrutinib with rituximab deepened responses during maintenance treatment for intermediate- or high-risk marginal zone lymphoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610272030PRIMZONEFULLFEED9854775) on October 28, 2026, and is solely responsible for the information contained therein.